What happened to BBR3464 and where to from here for multinuclear platinum-based anticancer drugs?
Dalton Transactions · 2025
DOI: 10.1039/d4dt02868f ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Dalton Transactions, 2025. Verfasst von Mia A Tesoriero und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Organoplatinum Compounds, Coordination Complexes, Platinum. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 107 Literaturangaben.
Abstract (Originalsprache)
The development of the trinuclear platinum( ii ) complex BBR3464 (also known as triplatin) in the late 1990s was meant to be a revolution in the field of platinum chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.
- School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, NSW, 2109, Australia. nial.wheate@mq.edu.au.
ORCID-Profile: Mia A Tesoriero, Nial J Wheate
Zitieren
APA
Tesoriero, M. A., & Wheate, N. J. (2025). What happened to BBR3464 and where to from here for multinuclear platinum-based anticancer drugs?. Dalton Transactions. https://doi.org/10.1039/d4dt02868f
Vancouver
Tesoriero MA, Wheate NJ. What happened to BBR3464 and where to from here for multinuclear platinum-based anticancer drugs?. Dalton Transactions. 2025. doi:10.1039/d4dt02868f
BibTeX
@article{Tesoriero2025,
author = {Tesoriero, Mia A and Wheate, Nial J},
title = {What happened to BBR3464 and where to from here for multinuclear platinum-based anticancer drugs?},
journal = {Dalton Transactions},
year = {2025},
doi = {10.1039/d4dt02868f}
}
EUVIMED